Overview

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Arena Pharmaceuticals

Criteria

Inclusion Criteria:

- Japanese ancestry

- Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening

- Having active UC confirmed by endoscopy

- Moderately to severely active UC

Exclusion Criteria:

- Severe extensive colitis

- Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence, history of
a fistula consistent with CD

- Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis